Trump signs executive actions to boost domestic drug manufacturing and tighten oversight on gain-of-function research, raising concerns over potential higher costs and shortages.
US services sector shows resilience amid inflation concerns, with growth picking up in April despite supply chain disruptions and tariff impacts.
Trump signs executive actions to boost domestic drug manufacturing and tighten oversight on gain-of-function research, raising concerns over potential higher costs and shortages.
US services sector shows resilience amid inflation concerns, with growth picking up in April despite supply chain disruptions and tariff impacts.